2012
DOI: 10.1111/j.1600-6143.2012.04134.x
|View full text |Cite
|
Sign up to set email alerts
|

Lymphocytic Bronchiolitis After Lung Transplantation Is Associated With Daily Changes in Air Pollution

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
43
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(43 citation statements)
references
References 28 publications
0
43
0
Order By: Relevance
“…It has been shown that azithromycin has a protective effect on lymphocytic bronchiolitis in the posttransplant setting for lung recipients (36). Generally, our program initiates azithromycin therapy at physician discretion in response to drops in lung function.…”
Section: Discussionmentioning
confidence: 99%
“…It has been shown that azithromycin has a protective effect on lymphocytic bronchiolitis in the posttransplant setting for lung recipients (36). Generally, our program initiates azithromycin therapy at physician discretion in response to drops in lung function.…”
Section: Discussionmentioning
confidence: 99%
“…The pathogenesis of AR however, is fundamentally different than the other injury patterns. While many cases of DAD, OP and LB are initiated by exposure related insults (e.g., aspiration, infection, pollution (13, 33, 60)), AR represents an allo-immune response. Transplant recipients with early AR may have had the early presence of circulating allo-responsive memory T-cells.…”
Section: Discussionmentioning
confidence: 99%
“…Since there are no effective treatments available for CLAD, the identification of risk factors is a key step towards both understanding CLAD pathogenesis and improving post-transplant outcomes. There are numerous “non-alloimmune” (e.g., respiratory infections (2-9), gastroesophageal reflux (10, 11), air pollution (12, 13), autoimmune reactivity (14, 15)) and “alloimmune” insults (e.g. acute cellular rejection (16-18)) which challenge the lung allograft.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, it follows that thoughtful, informationweighted and value-driven decision making will always be required to manage the intrinsic risk trade-off between alloreactivity and infection/toxicity that will never be able to be completely resolved with the use of these more specific but nevertheless still ''blunt'' immunosuppressant agents. These trade-offs are particularly relevant in the LTR who routinely receives a non-HLA matched donor organ which is necessarily fully exposed to aero-environmental irritants, allergens and infections [155,156] and will, therefore, require a vigilant and indefinite review of immunosuppression strategy.…”
Section: Individual Patient Management Issuesmentioning
confidence: 99%